Clinical Trial Goal
To find out if the combination of brentuximab and nivolumab is safe and works well to treat Hodgkin lymphoma that has relapsed or is refractory before BMT in children and adults
You may be able to join this trial if you:
- Are 12 years old or older
- Have Hodgkin lymphoma that has relapsed or is refractory
- Have received at least one of the following (your doctor can tell you this):
- Brentuximab
- An immune checkpoint inhibitor like nivolumab or pembrolizumab
- Do not have lymphoma in your brain or spinal cord
- Have not had a blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Brentuximab is a monoclonal antibody-drug conjugate that targets CD30 on certain cells.
Nivolumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Nivolumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Brentuximab – Given as intravenous (IV) infusions 1 time
- Nivolumab - Given as IV infusions 1 times
Patients with lymphoma that responds after 3 months of treatment may stop and proceed to BMT.
You may continue treatment for up to 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat Hodgkin lymphoma before BMT is new and unproven.
Locations
Emory Saint Joseph's HospitalRECRUITING
Atlanta, Georgia
Marcela Algave, CRN, 678-843-7544, marcela.rodrigues.algave@emory.edu
Emory University Hospital/Winship Cancer InstituteRECRUITING
Atlanta, Georgia
Contacts:
- Kristie A. Blum, 404-778-5933, kablum@emory.edu
- Blair Dykeman, blair.dykeman@emory.edu
Sponsors
collaborator: National Cancer Institute (NCI), lead: Emory University
